Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Consumer Defensive · Tobacco

Altria

MO · a US exchange · USD · Market cap $127.0B · 5,900 employees

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States.

FAIL · Does not pass the screen
77.46 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price77.46 USD at the 17 Nov 2026 close
  • Our value readFair vs our fair value, as of 17 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.69)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $85.00 to $148.05, base estimate $85.00 (screen dated 2026-11-17).

Current read
Markup ?
Fair · screened 2026-11-17
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.69, read 2026-11-13
  • Ethical does not pass the values gate
Price77.46 USD
Fair value85.00
Ethical score10.0/100
Value readFairas of 17 Nov 2026
Our investment reviews on this name
2026-10-26Read Markup73.84+4.9% to today ✓Accumulation gives way to Markup after a 7% rise in 3 weeks
2026-10-02Read Accumulation68.82+12.6% to today ✓Distribution gives way to Accumulation
2026-08-30Read Distribution66.94+15.7% to today Markup gives way to Distribution after a 7% slide in 8 weeks
2026-07-02Read Markup72.19+7.3% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Altria holds its Markup at $77.46. Consolidating, no directional conviction, held for 50 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 50 days
Price at the screen$77.46
Valuation15.74 trailing · 12.89 forward price to earnings
Values screenFAIL · score 10.0
Beta0.46
The Workings

Five Screens, Shown in Full

Does not pass. Business activity screen

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Business activity: Tobacco Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Altria does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when MO's ethical verdict changes

Today MO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 17 Nov 2026: it trades at roughly a 9% discount to our $85.00 fair value, 3.60% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

85.00Conservative85.00Base case148.05Growth case 77.46Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 8.9% discount to the base estimate.

The Street's Range
59.00Street low 73.00Street average 85.00Street high 77.46Price

Third-party analyst targets: 11 covering, consensus Hold. The average target sits −6% from the screen price.

Reading the gap · Our model sees value the Street hasn't fully caught up to yet.

Price History & Projections

Where our models see it going: fair-value estimate $85.00, with a range of $85.00 to $148.05, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business: 39% profit margins. It trades close to our $85.00 fair value, so the easy discount is gone; you would be paying up for the quality.

The fundamentals · plain-English read
Forward P/E12.9xexpensive even after accounting for its growth
Trailing P/E15.7xreasonably valued
EPS, trailing4.85
EPS, forward5.92
Revenue growth+3.6%slow but positive growth
Profit margin39.3%highly profitable on every dollar of sales
FCF yield5.56%
Dividend yield5.63%
Current ratio0.58below 1: short-term bills exceed liquid assets
Beta0.46barely tracks the market's swings
Short interest, float0.02%
52-week range54.70 - 79.87
Market cap$127.0B
Employees5,900

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

MO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Markup $77.39 -0.8% Entry 23

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $73.

2026-11-05 Markup $78.01 +5.0% Entry 22

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $73.

2026-10-29 Markup $74.31 +0.6% Entry 21

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Markup $73.84 +0.0% Entry 20

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Markup $73.84 +0.0% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markup · changed $73.84 +0.0% Entry 18

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Accumulation $73.84 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-24 Accumulation $73.84 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Accumulation $73.84 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Accumulation $73.84 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (11 analysts) rates it hold, with a mean price target of $70. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on MO

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in MO's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · MO
DateInsiderTitleTypeSharesValue
2026-05-14 SHANKS VIRGINIA E Director 2,571 ·
2026-05-14 YZAGUIRRE MARIO MAX Director 2,571 ·
2026-05-14 CLARKE IAN L.T. Director 2,571 ·
2026-05-14 KELLY-ENNIS DEBRA J Director 2,571 ·
2026-05-14 DAVIS ROBERT MATTHEWS Director 2,571 ·
2026-05-14 STRAHLMAN ELLEN Director 2,571 ·
2026-05-14 CONNELLY MARJORIE MARY Director 2,571 ·
2026-05-14 STODDART RICHARD S. Director 2,571 ·
2026-05-14 MCQUADE KATHRYN ANN BOVA Director 4,656 ·
2026-05-13 MANCUSO SALVATORE Chief Executive Officer 40,634 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming MO
DatePoliticianPartyTypeAmount
2026-11-04 Gil Cisneros Democrat buy 250K–500K
2026-10-20 Gil Cisneros Democrat buy 1K–15K
2026-10-19 Ro Khanna Democrat buy 1K–15K
2026-10-15 Gil Cisneros Democrat buy 50K–100K
2026-10-15 Ro Khanna Democrat buy 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $68.61 +6.4% · $1,064 +6.4%
2 months $67.38 +8.4% · $1,084 +8.4%
3 months $66.60 +9.6% $1.06 $1,112 +11.2%
6 months $56.71 +28.7% $2.12 $1,325 +32.5%
1 year $54.71 +33.5% $4.20 $1,411 +41.1%
2 years $40.17 +81.8% $8.24 $2,023 +102.3%
3 years $35.77 +104.1% $12.12 $2,380 +138.0%
5 years $33.72 +116.5% $19.40 $2,740 +174.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever MO does next, these words stay.

Altria · MO · Markup · $77.46
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.